

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>Versant Vantage I, L.P.</u>			2. Issuer Name and Ticker or Trading Symbol <u>Aprea Therapeutics, Inc. [ APRE ]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) _____ Other (specify below) _____		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <u>10/07/2019</u>			6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person		
<u>ONE SANSOME, SUITE 3630</u>			4. If Amendment, Date of Original Filed (Month/Day/Year)					
(Street) <u>SAN FRANCISCO CA 94104</u>								
(City)	(State)	(Zip)						

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	10/07/2019		C		1,993,658	A	(1)	2,006,328	I	See footnotes <sup>(2)(3)(5)</sup>
Common Stock	10/07/2019		C		512,995	A	(1)	2,519,323	I	See footnotes <sup>(2)(3)(5)</sup>
Common Stock	10/07/2019		P		333,333	A	\$15	333,333	D <sup>(4)(5)</sup>	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series B Convertible Preferred Stock	(1)	10/07/2019		C			1,993,658	(1)	(1)	Common Stock	1,993,658	(1)	0	I <sup>(2)(3)(5)</sup>	See footnotes <sup>(2)(3)(5)</sup>
Series C Convertible Preferred Stock	(1)	10/07/2019		C			512,995	(1)	(1)	Common Stock	512,995	(1)	0	I <sup>(2)(3)(5)</sup>	See footnotes <sup>(2)(3)(5)</sup>

1. Name and Address of Reporting Person\*  
Versant Vantage I, L.P.

(Last) (First) (Middle)  
ONE SANSOME, SUITE 3630

(Street)  
SAN FRANCISCO CA 94104

(City) (State) (Zip)

1. Name and Address of Reporting Person\*  
Versant Vantage I GP, L.P.

(Last) (First) (Middle)  
ONE SANSOME STREET, SUITE 3630

(Street)  
SAN FRANCISCO CA 94104

(City) (State) (Zip)

1. Name and Address of Reporting Person\*  
Versant Vantage I GP-GP, LLC

(Last) (First) (Middle)

ONE SANSOME STREET, SUITE 3630

(Street)

SAN FRANCISCO CA

94104

(City)

(State)

(Zip)

**Explanation of Responses:**

1. These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.
2. These Shares and Preferred Stock are directly held by Versant V Luxco S.a r.l.
3. Versant V Luxco S.a r.l. is majority owned by Versant Venture Capital V, L.P. and minority owned by Versant Ophthalmic Affiliates Fund I, L.P., Versant Affiliates Fund V, L.P. (together with Versant Venture Capital V, L.P. and Versant Ophthalmic Affiliates Fund I, L.P. the "Versant Funds") and Versant Venture Capital V (Canada) LP ("Versant Canada"). Versant Ventures V, LLC ("Ventures V") is the general partner of each of the Versant Funds. Versant Ventures V GP-GP (Canada), Inc. is the general partner of Versant Ventures V (Canada), L.P., which is the general partner of Versant Canada. Each of the Versant Funds, Versant Canada, Versant Ventures V (Canada), L.P., Versant Ventures V GP-GP (Canada), Inc. and Ventures V may be deemed to indirectly beneficially own the shares beneficially owned by Versant V Luxco S.a r.l., but each disclaims such beneficial ownership except to the extent of its pecuniary interest therein.
4. These Shares are directly held by Versant Vantage I, L.P. Versant Vantage I GP-GP, LLC is the general partner of Versant Vantage I GP, L.P., which is the general partner of Versant Vantage I, L.P. Each of Versant Vantage I GP-GP, LLC and Versant Vantage I GP, L.P. may be deemed to indirectly beneficially own the shares beneficially owned by Versant Vantage I, L.P., but each disclaims such beneficial ownership except to the extent of its pecuniary interest therein.
5. Samuel D. Colella ("Colella"), William J. Link ("Link"), Bradley Bolzon, Ph.D ("Bolzon"), Kirk G. Nielsen ("Nielsen"), Thomas Woiwode ("Woiwode"), Jerel C. Davis ("Davis") and Robin L. Praeger ("Praeger") are managing directors of Ventures V. Bolzon, Woiwode, Davis, Praeger, and Clare Ozawa ("Ozawa") are managing directors of Versant Vantage I GP-GP, LLC. Each of Colella, Link, Bolzon, Nielsen, Woiwode, Praeger, Davis and Ozawa disclaim beneficial ownership of the Shares reported herein, except to the extent of his or her pecuniary interest therein.

/s/ Versant Vantage I, L.P. By:  
Versant Vantage I GP, L.P. Its:  
General Partner By: Versant  
Vantage I GP-GP, LLC Its: 10/07/2019  
General Partner By: Robin L.  
Praeger Its: Managing Director

/s/ Versant Vantage I GP, L.P. By:  
Versant Vantage I GP-GP, LLC  
Its: General Partner By: Robin L. 10/07/2019  
Praeger Its: Managing Director

/s/ Versant Vantage I GP-GP,  
LLC By: Robin L. Praeger Its: 10/07/2019  
Managing Director

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.